The Market Reports

Synopsis

The global market for Polydeoxyribonudeotide (PDRN) was estimated to be worth US$ 72.1 million in 2024 and is forecast to a readjusted size of US$ 540 million by 2031 with a CAGR of 32.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Polydeoxyribonudeotide (PDRN) cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

PDRN is deoxyribonucleic acid(DNA) product, mainly comes from semen and roe of fish, rapidly repair injured scars. It can promote the collagen synthesis on the cell surface, reverse aging signs. PDRN is the excellent skin repair product widely used for both high-end beauty products and medical products. Strong functions of anti-radiation and shrinking pores, make skin appears brightly and elastically.

Polydeoxyribonucleotide (PDRN) and polynucleotide (PN) are regenerative materials extracted from the regenerative cell (sperm and testicle) gene segment (DNA) of salmon or trout. The molecular sizes of PDRN and PN are different (PN is bigger) and they are safe biogenic substances approved by the Ministry of Food and Drug Safety. PDRN are often used in pharmaceuticals for tissue regeneration and cornea regeneration as well as treatment and tissue restoration of wounds. PN is often used for medical devices (tissue regeneration) for skin regeneration, articular cartilage regeneration, and osteogenic tissues.

Both PDRN and PN are included in the report.

As a product of regenerative medicine, PDRN can synthesize DNA from damaged or hypoxic tissues, activate the regeneration of endogenous growth factors such as FGF, IGF, and EGF, accelerate cell metabolism, and improve skin repair and regeneration capabilities. The fiber network full of collagen and elastin can achieve skin rejuvenation, improve skin microenvironment, increase skin thickness, etc., so as to achieve the effect of improving problem skin.

The PDRN market has shown a significant growth trend in recent years, mainly driven by the field of regenerative medicine and tissue engineering, as well as the field of aesthetics. Demand for innovative solutions in medical fields such as wound healing, dermatology, orthopedics is driving the demand for PDRN products and therapies.

In terms of product types, freeze-dried powder occupies an important position, dominated with 65% market share in 2024, preferred for stability and versatility in pharmaceuticals and cosmetics. While PDRN Solutions are growing demand in injectables (e.g., mesotherapy), especially in Korea’s "salmon needle" treatments. Expected to surge due to ease of clinical applicationAt the same time, in terms of application, the share of Medical Aesthetics (Mesotherapy) in 2024 is about 32%, used in "regenerative hydrogels" for collagen synthesis and anti-inflammatory effects.

The major global manufacturers of Polydeoxyribonudeotide (PDRN) include HTL Biotechnology, Ruijiming Biological, PharmaResearch Co., Ltd., Humedix, ReaLi Tide Biological, HENGYU BIOPH, Mastelli, Dongkook, BR PHARM, BMI KOREA, BNF Solution, etc. In 2024, the world's top three vendors accounted for approximately 56% of the revenue.

As a new type of regenerative material, PDRN has multiple activities such as promoting skin damage repair, anti-inflammatory, promoting angiogenesis, improving tissue microcirculation, etc. It has broad application prospects in the fields of medical devices, medicine, cosmetics, health foods, daily chemical products, medical cosmetology, etc. In the future, with the rise of medical beauty consumption and the expansion of application fields, the scale of the PDRN market will further expand. The PDRN market is poised for explosive growth, anchored by Asia-Pacific’s dominance (Korea/China) and diversification into cosmetics/wound care. Key developments include China’s regulatory openings, plant-based innovations, and the rise of "regenerative aesthetics."

This report aims to provide a comprehensive presentation of the global market for Polydeoxyribonudeotide (PDRN), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Polydeoxyribonudeotide (PDRN) by region & country, by Type, and by Application.

The Polydeoxyribonudeotide (PDRN) market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polydeoxyribonudeotide (PDRN).

Market Segmentation
By Company

• HTL Biotechnology
• ReaLi Tide Biological
• PharmaResearch Co., Ltd.
• Humedix
• Ruijiming Biological
• Bloomage Biotech
• HENGYU BIOPH
• Mastelli
• Dongkook
• BR PHARM
• BNC Global
• BMI KOREA
• BNF Solution
• Nanjing Letop Biotechnology
• Topscience Biotech
• Freda Biotechnology
• Shebah Biotech
• APR Corporation
• Kolmar Korea
• PORIBIO INC.

Segment by Type

• Powder
• Solution

Segment by Application

• Mesotherapy
• Bone Injection & Dermal Fillers
• Pharmaceutical
• Cosmetic
• Wound Healing Products and Others

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.